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Abstract
HIV replication is only partially controlled by HIV-specific activated effector T cells in chronic HIV infection and strategies are
warranted to improve their efficacy. Chronic T cell activation is generally accompanied by regulation of antigen-specific T
cell responses which may impair an effective control of chronic infections. The impact of HIV-induced T cell regulation on
individual patients’ disease progression is largely unknown, since classical T cell activation assays reflect net activation with
regulation as unknown contributing factor. We here explore a quantitative parameter for antigen-induced cytokine-
mediated regulation (RAC) of HIV-specific effector T cell activation by functional antibody-blockade of IL-10 and transforming
growth factor-b. HIV Env- and Gag-specific T cell activation and RAC were estimated in peripheral blood mononuclear cells
from 30 treatment-naı̈ve asymptomatic HIV-infected progressors (CD4 count 472/ml, HIV RNA 37500 copies/ml) stimulated
with overlapping peptide panels for 6 days. RAC was estimated from differences in T cell activation between normal and
blocked cultures, and related to annual CD4 loss, immune activation (CD38) and microbial translocation (plasma
lipopolysaccharides). RAC was heterogeneously distributed between individual patients and the two HIV antigens. Notably,
RAC did not correlate to corresponding classical activation. Env RAC correlated with CD38 and CD4 loss rates (r.= 0.37,
p =,0.046) whereas classical Gag activation tended to correlate with HIV RNA (r =20.35, p = 0.06). 14 patients (47%) with
low RAC’s to both Env and Gag had higher CD8 counts (p = 0.014) and trends towards lower annual CD4 loss (p = 0.056) and
later start with antiretroviral treatment (p = 0.07) than the others. In contrast, patients with high RAC to both Env and Gag
(n = 8) had higher annual CD4 loss (p = 0.034) and lower CD8 counts (p = 0.014). RAC to Env and Gag was not predicted by
classical activation parameters and may thus provide additional information on HIV-specific immunity. RAC and other
assessments of regulation deserve further in-depth exploration.
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Introduction
Chronic human immunodeficiency virus type 1 (HIV) infection
leads to a variable but progressive loss of immune functions in
most patients. The progression rate is mainly influenced by two
opposing factors, namely HIV-associated chronic immune activa-
tion [1–3] and the efficacy of HIV-specific T cell responses [4,5].
Chronic immune activation expressed by CD38 on T cells,
correlates strongly to disease progression and mortality [6–8]. It is
partly sustained by enhanced systemic translocation of microbial
products such as bacterial lipopolysaccharide (LPS) [9,10] and
induces polyclonal B and T cell activation [11,12], accelerated T
cell turnover [13,14] and immune exhaustion [2,15]. Effective
viral control, on the other hand, seems to depend on the presence
of polyfunctional HIV-specific CD8+ T cells [4].
A less clarified aspect of HIV-specific immunity is downregu-
lation of the HIV-specific effector T cells, where regulatory T cells
(Treg) play a central role [16,17]. Regulation of effector T cells
protects the host from damage in chronic infection, but may also
impair effective immune control. It is mediated by a number of
mechanisms, including the expression of inhibitory receptors in the
immune synapse such as CTLA-4 [18] and programmed death-1
(PD-1) [19,20], or via soluble inhibitory cytokines, particularly IL-
10 and transforming growth factor-b (TGF-ß). These two key
inhibitory cytokines impede pro-inflammatory responses by T
cells, natural killer cells, monocytes and macrophages and are
secreted by a number of cell types including Treg [21–24].
The efficacy of T cell responses depends on the sum of
stimulatory and regulatory signals. T cell regulation has been
intensively studied, but with focus on single regulating mecha-
nisms. However, how these various regulating mechanisms finally
and in concert influence HIV-specific T effector cells and disease
progression in individual patients has been little explored. This
might be assessed for T cells in vitro by blocking downstream
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intracellular regulatory signal pathways during antigen stimula-
tion. Recently we tested such an in vitro quantitative parameter for
regulation in patients on antiretroviral treatment (ART) during
reboost with a Gag peptide-based therapeutic HIV vaccine [25].
We estimated vaccine-specific cytokine-mediated regulation of
CD8+ T cell responses by blocking the effects of IL-10 and TGF
(antigen-induced cytokine-mediated regulation, RAC). Notably,
changes in RAC explained the substantial variations in booster
efficacy, including cases where vaccine responses waned after each
booster.
Since RAC seemed to reflect important features of HIV vaccine-
specific T cell immunity during immunization, we hypothesized
that the same parameter also would provide novel information in
natural chronic HIV infection. In this study, we therefore
compared RAC and activation of Gag- and Env-specific T effector
cells in treatment-naı̈ve patients. We found RAC to be heteroge-
neous, both between individual patients and between the two HIV
antigens, and unfavourably related to HIV progression.
Materials and Methods
Patients
Thirty asymptomatic HIV-1 seropositive ART-naı̈ve viremic
progressors were included (23 males, 7 females). Their clinical
characteristics are shown in Table 1. The patients represented a
spectre of HIV-associated immune activation determined by
CD38 densities on total CD8+ and CD8+PD-1+ T cells [8] and
were chosen from a larger cross-sectional prospective study on
immunological factors in HIV. The study was approved by the
Norwegian South-Eastern Regional Committee for Medical and
Health Research Ethics. Informed consent was signed by each
participant.
Activation Assays and Flow Cytometry
Peripheral-blood mononuclear cells (PBMC) were isolated using
Cell Preparation Tubes (Becton Dickinson (BD), CA, USA) and
preserved, thawed and cultured in serum-free AIM culture
medium containing 0.5% human albumin at 5% CO2 at 37uC,
as described elsewhere [26]. To evaluate activation and prolifer-
ation parameters, the fractions of T cells co-expressing CD25 and
HLA-DR [27] or having low carboxyfluorescein succinimidyl ester
(CFSEdim) signal [28] were compared. PBMC were pulse-labelled
with CFSE (3 mM, 5 min (Invitrogen Molecular Probes, OR,
USA) as detailed previously [29] and subjected to HIV antigens
(four HIV-1 Gag p24 consensus peptide sequences, represented by
15-mer overlapping by 2 amino acid panels [29] and non-HIV
antigens (23 15-mer peptides from cytomegalovirus, Epstein-Barr
virus and influenza virus (CEF, Mabtech, Sweden)).
For the estimates of antigen-specific cytokine-mediated regula-
tion of T cell activation (RAC), cryopreserved PBMC were thawed,
washed and reconstituted in serum-free AIM overnight, and then
stimulated with complete 15-mer Env or Gag overlapping peptide
panels (NIH AIDS Research and Reference Reagent Program,
MD, USA) as detailed elsewhere [30]. Peptide panels in all
experiments were used at 2 mg/ml/peptide. Peptide-exposed and
control cultures were in parallel incubated with inhibitory
monoclonal antibodies (mAbs) to IL-10 and TGF-ß, each at
10 mg/ml final concentration according to the instructions by the
manufacturer (R&D Systems Europe, Abingdon, UK), a concen-
tration that abolished IL-10 in cell culture supernatants (Luminex
assay of supernatants from antigen stimulated T cells cultured for 6
days, data not shown). Staphylococcal enterotoxin B (Sigma-
Aldrich, MO, USA) was used as positive control at 0.5 mg/ml.
Cells were cultured at 37 Co in 5% CO2 for 6 days, and then
harvested, stained and prepared for flow cytometric analysis as
previously described [31]. The following fluorochrome-labelled
mAbs were used: CD3 Pacific Blue, CD8 AmCyan, HLA-DR PE-
Cy7 (BD), CD4 PE and CD25 APC (eBioscience, CA, USA). 7-
aminoactinomycin (7-AAD, BD) was added to discriminate
between viable and non-viable cells according to the manufactur-
er. Flow cytometry data were obtained with a BD FACS Canto II
with BD Diva software v6.1. Only lymphocyte and lymphoblast
gates containing live 7-AAD2 CD3+ T lymphocytes were
evaluated.
Quantification of Env and Gag Related T Cell Activation
Antigen-specific activation of T cell subsets was defined as the
difference in activation marker between peptide-stimulated cells
and corresponding control cells without peptides. In preceding
experiments exploring T cell regulation by HIV vaccine antigens
in patients on ART, regulation and activation were determined by
differences in proliferation (CFSEdim) in CFSE pulse-labelled cells
[25]. In our experience, thawed PBMC samples from ART-naı̈ve
individuals are more vulnerable to toxic effects of CFSE [32], even
after short exposure and low concentrations. We therefore
compared fractions of CFSEdim, defined by median fluorescence
intensities equal to or below the second proliferated generation in
CFSE-labelled PBMC, and fractions of CD25+HLA-DR+. These
parameters reflect overlapping aspects of T cell activation [27], i.e.
proliferation, IL-2 receptor expression and increased HLA class II
expression), as illustrated in Fig. 1A, with correlating activation
results after exposure to both non-HIV and HIV antigens (Fig. 1B).
T cell activation within the cohort was therefore determined by the
frequency of subsets co-expressing CD25 and HLA-DR in
antigen-stimulated cultures corrected for unstimulated controls
[27].
Quantification of Env- and Gag-induced Cytokine-
mediated T Cell Regulation
In parallel with classical activation cultures, IL-10 and TGF-ß
blocked activation was determined as the difference between
antigen-stimulated and control samples that received IL-10 and
TGF-ß blocking mAbs (Fig. 2A). The magnitude of antigen-
induced IL-10 and TGF-ß mediated regulation of T cell activation
(RAC) was calculated by the difference in activation between these
two culture conditions (Fig. 2B). RAC calculated by CFSE
dim
Table 1. Cohort characteristics.
All (n = 30)
Median (IQ range)
Age (years) 42 (33–49)
Time HIV seropositive (months) 57 (16–83)
CD4+ T cell count (6106/l) 472 (325–695)
CD8+ T cell count (6106/l) 1084 (788–1828)
HIV-RNA in plasma (copies/ml) 37500 (2300–72000)
Annual CD4 T cell count loss (cells 6106/l) 11 (269–177)
b2-microglobulin in serum (mg/l) 2.5 (1.9–3.3)
CD38 on CD8+ T cells (molecules/cell) 3285 (1834–7226)
CD38 on CD8+CD38+PD-1+ T cells (molecules/cell) 4127 (2095–8704)
LPS (pg/ml) 70 (59–86)
doi:10.1371/journal.pone.0085604.t001
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EDTA plasma obtained concurrently with the isolation of
PBMC was separated and snap-frozen at 270uC. LPS was later
measured en bloc in thawed plasma with the Limulus Amebocyte
Lysate chromogenic assay (Lonza, MD, USA) according to the
manufacturer’s instructions with the following modifications:
Samples were diluted 10-fold to avoid interference with back-
ground colour and preheated to 70uC for 12 minutes prior to
analysis to dissolve immune complexes, as previously described
[10].
Plasma Levels of Cytokines and Chemokines
Soluble cytokines representing Th1 (TNF-a, INF-c) and Th2
(IL-4, IL-5, IL-10 and IL-13) profiles were measured in snap-
frozen EDTA plasma (see above) using Bio-Plex XMap technology
(TX, USA) with a Luminex IS100 instrument (BIO-RAD, CA,
USA) and Bio-Plex manager Software v6, according to the
instructions by the manufacturer.
Statistics
To not underestimate regulation, antigen-specific activation
readouts relative to control cultures were treated as raw data. Non-
parametrical statistics were applied throughout the study; Mann-
Whitney U- and Kruskal-Wallis test to compare differences
between two or more groups, and Spearman Rank for correlation
analysis. All continuous variables are presented as medians
Figure 1. Comparison of CD25+HLA-DR+ expression and CFSEdim as measures for antigen-induced activation and regulation of T
cells. CFSE-labelled PBMC from 28 HIV-infected individuals were stimulated for 6 days with peptides encoding either HIV p24 consensus regions (HIV
Ag) or a pool of commonly encountered non-HIV viral peptides (Non-HIV Ag). A. Co-expression of CD25 and HLA-DR on live CD8+CD3+ T cells on
non-divided CFSEhigh (left panel) and proliferated CFSEdim T cells (right panel), showing excessive difference in fractions of CD25+HLA-DR+ in the
activated subset to the right. B. Scatter plots of activation measured in the same culture by CFSEdim or HLA-DR+CD25+, respectively, to non-HIV (+)
and HIV antigen (%) within the CD8+ (left panel) and CD4+ (right panel) T cell subsets. Significant and high correlations obtained for both Non-HIV
antigens (CD8+, r = 0.92, p,0.001: CD4+ r = 0.64, p,0.001) and HIV Gag p24 (CD8+, r = 0.90, p,0.001: CD4+ r = 0.71, p,0.001).
doi:10.1371/journal.pone.0085604.g001
A Parameter for HIV-1 T Cell Regulation
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e85604
(interquartile range). The Fisher Exact test was performed to
analyse cross-tabulated categorical data. The annual CD4 count
loss rates were calculated as previously described [26]. Statistica v7
statistical software (StatSoft Inc., OK, USA) was used for all
analysis. A p-value #0.05 was regarded as significant.
Results
Cohort Characteristics Including Parameters for Immune
Activation
Thirty asymptomatic ART-naı̈ve HIV-infected patients (CD4+
T cell counts, 472; HIV RNA, 37,500 copies/ml, medians) were
included to represent a spectrum of HIV-associated immune
activation. CD38, microbial translocation (LPS) and HIV RNA
correlated (r between 0.44–0.60, p,0.02, detailed data not
shown). In keeping with previous observations where CD38
density on CD8+ T cells and on CD8+PD-1+ cells had higher
correlation with other progression markers than frequencies of
CD38+HLA-DR+CD8+ T cells [8,25,26], CD38 density was used
to represent chronic immune activation in the following analysis.
T cell Activation by Gag and Env
T cell activation to Gag and Env peptide panels varied between
patients and was generally higher for Gag, in keeping with
previous observations [30] (Fig. 3A, x-axis). Moreover, Gag and
Env activation correlated within both the CD8+ (r = 0.40,
p = 0.027) and CD4+ (r = 0.53, p = 0.003) T cell subsets (data not
shown).
Variable T Cell Regulation (RAC) without Correlation to
Activation
A parameter for HIV antigen-specific cytokine-mediated T cell
regulation (RAC) was determined by parallel antigen activation
cultures and controls in the absence and presence of IL-10 and
TGF-ß blocking mAbs. It should be noted that RAC calculated by
CFSE correlated significantly with RAC determined by the co-
expression of CD25 and HLA-DR (Fig. 2C).
A substantial variability was observed in RAC related to Gag
and Env exposure (Fig. 3A, y-axis). No correlations were found
between RAC induced by the two HIV antigens (Fig. 3B), in
contrast to the corresponding activation. Perhaps more impor-
tantly, Gag or Env related RAC and corresponding activation did
not correlate (Fig. 3A). Thus, RAC quantified this way could not
have been predicted by the conventional activation assay.
Activation and RAC to HIV-antigens in Relation to
Progression Markers
We next explored how RAC was related to markers of chronic
HIV activation (CD38 density on CD8+ T cells and PD-1 subsets
[8,26]), microbial translocation (LPS), HIV replication and annual
CD4+ T cell loss rates. Significant and unfavourable correlations
were revealed between Env related RAC in either T cell subsets
and chronic immune activation (CD8+, r = 0.41, p = 0.024) and
CD4 loss rates (CD4+, r = 0.39, p = 0.032), whereas Gag-induced
T cell activation tended to correlate with HIV RNA (CD8+,
r =20.35, p = 0.060). These heterogeneous relations are depicted
in Fig. 4, for simplicity illustrated by overall CD3+ T cell activation
and regulation.
Clusters of Patients with Low and High HIV Antigen-
induced Regulation
One cluster of patients appeared to have low RAC induced by
both Gag and Env within the CD4+ and CD8+ subsets (Fig. 3B).
The same cluster was seen when we examined RAC for all CD3
+ T
cells (Fig. 5A). This is in keeping with the notion that IL-10 and
Figure 2. Schematic outline and examples of the T cell
regulation assay. A. Schematic outline of the assay measuring
antigen-induced cytokine-mediated induced regulation (RAC) of T cell
activation by IL-10 and TGF-ß. Left panel shows a conventional T cell
assay where the final activation measurements are regarded as net
results of proinflammatory and regulatory signals. Right panel show a
possible outcome when blocking T cell regulatory cytokines. T cell
regulation (D) is here defined as the difference in activation responses
to the same antigen between these panels. B. Detailed example
calculating classical activation (upper panels) and regulation (calculated
from activation in the presence blocking mAbs to IL-10 and TGF, lower
panels), all gated for viable CD8+ CD3+ T cells. Activation in both upper
and lower panels calculated as the difference (D) in CD25+HLA-DR+
fractions between control and antigen-stimulated (Ag+). Note a typical
slight increase in background activation (lower left panel). Regulation
(RAC) calculated as the difference (D) between activation in cytokine-
blocked culture and conventional activation culture. C. Scatter plots of
regulation calculated in the same cultures by CFSEdim or HLA-
DR+CD25+, respectively, for the CD8+ (l, r = 0.67, p,0.001) and CD4+
(U, r = 0.45, p = 0.026) T cell subsets.
doi:10.1371/journal.pone.0085604.g002
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TGF-ß inhibit both the CD4+ and CD8+ T cell subsets [23,33].
This cluster of patients with overall low RAC induced by Gag and
Env was defined as Low regulators [n = 14 (47%)] (Fig. 5A) whereas
the remaining 53% (n = 16) were termed High regulators. Notably,
the magnitude of RAC in suppressing corresponding activation was
quite substantial for the High regulator patients, as illustrated by
high RAC/Activation-ratios [3.0 (0.8–4.1) for Env and 2.4 (0.8–
12.4) for Gag, respectively] (data not shown). Again, conventional
activation for CD3+ T cells did not correlate with the
corresponding RAC. Thus, High regulators could not have been
identified by the activation assay (Fig. 5B).
The Low and High regulator patient groups were also
compared with respect to clinical parameters, immune activation,
LPS and conventional activation. High regulators had lower CD8
counts in blood (p = 0.031) and a trend towards faster CD4 loss
rates (p = 0.056) (Table 2). High regulators also had significantly
lower levels of plasma Th1 cytokines INF-c (p = 0.04) and TNF-a
(p = 0.04) (Fig. 6), but no differences were found for Th2 cytokines
including IL-10 between the two regulation groups.
Characterization of Study Patients with High HIV
Antigen-induced Regulation
Examining the High regulator patients in more detail, we found
that they either had substantial RAC induced by Gag (denoted Gag
regulators, n = 8), or by both Gag and Env (Pan regulators, n = 8)
(Fig. 5A). Gag regulators appeared more similar to Low regulators
in most parameters except that they had less conventional
activation to both Gag (CD4+ subset, p = 0.016) and Env
(p = 0.025). Pan regulators, on the other hand, had a profile
compatible with more accelerated disease, such as higher annual
CD4 loss (221 vs 210 cells/year, p = 0.034), lower CD8 counts
(median 841 vs 1458 cells/ml, p = 0.014) and possibly lower CD4
counts (median 254 vs 488 cells/ml, p = 0.065) compared with the
Low regulator patients (Fig. 6). Thus, one might speculate whether
Gag and Pan regulators represent a continuum of an unfavourable
regulator phenotype which could not be identified by the classical
activation assay. Finally, of the 14 patients who had started ART
according to current guidelines within one year post-inclusion,
more patients tended to be Pan regulators than belonging to the
other subgroups (6 of 8 vs. 8 of 22, p = 0.07).
Figure 3. Insignificant relations between T cell activation and RAC induced by Env and Gag peptide panels. A. Relations between
regulation and activation to Env (left panels) and Gag (right panels) within the CD4+ and CD8+ T cell subsets respectively, correlation coefficients
indicated. B. Relations between Env- and Gag-induced regulation within the CD4+ (right panel) and the CD8+ (right panel) T cell subsets, respectively,
correlation coefficients indicated.
doi:10.1371/journal.pone.0085604.g003
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Discussion
HIV-specific T effector cells are potentially able to control viral
replication in HIV infection, but their responses are critically
weakened by the initial loss of HIV-specific CD4+ T cells, viral
immune escape, and T cell exhaustion driven by immune
activation [5,34]. An additional counteracting factor might be
the regulation of effective HIV specific T effector cells. We here
assessed a functional quantitative parameter for T cell regulation
(RAC) which we think could be relevant when evaluating HIV
infected patients and developing therapeutic vaccines. Therapeutic
vaccines might play an essential role in a future cure for HIV by
inducing effective T cell responses against re-activated, latently
infected cells [34]. Theoretically, pre-existing or induced regula-
tion can evoke T cell anergy and thus hamper the effects of
therapeutic vaccination in some patients. This notion was
supported by our recent observation where changes in RAC
explained variable and in some cases negative responses to
therapeutic HIV vaccine boosters [25].
To our knowledge, this is the first attempt to determine RAC or
similar quantitative parameters for HIV antigen-specific regula-
tion in chronically infected treatment-naı̈ve patients. The study
was motivated by our expectation that RAC would provide
Figure 4. Relations between Env- and Gag-induced RAC and activation and markers related to progression of chronic HIV infection.
RAC and corresponding activation (x-axis), for simplicity represented as overall CD3+ estimates (CD4+ plus CD8+ combined) induced by Env and Gag
peptide panels, respectively, and in relations to various progression markers (y-axis). Spearman rank r and corresponding p-values indicated, values
with p,0.10 bolded.
doi:10.1371/journal.pone.0085604.g004
A Parameter for HIV-1 T Cell Regulation
PLOS ONE | www.plosone.org 6 January 2014 | Volume 9 | Issue 1 | e85604
additional prognostic information. We found considerable vari-
ability in RAC not only between individual patients, but also
between the two tested HIV antigens. Thus, our data suggest that
at least in some patients, RAC does not reflect ‘‘global’’ regulation
of HIV antigens. RAC was in some cases substantial, exceeding
activation more than ten-fold. Moreover, RAC did not relate to
corresponding conventional activation readouts, showing that it
provided additional otherwise hidden information.
This exploratory approach to characterize a parameter
apparently reflected at least some aspects of cytokine-mediated
regulatory ‘‘capacity’’ in the individual patient. However, although
our data suggest that RAC can differentiate HIV-infected patients
in a new way and may reflect processes that are related to
progression of HIV, our choices of assay read-out and culture
conditions needs to be commented: Several assays are frequently
used to assess HIV-specific T cell activation and function. For
example, polyfunctional T cells in 6 to 18 h cultures have been
shown to coincide with control of viral replication [32]. However,
we did not prioritize this assay due to shortage of cells from this
clinically well-defined cohort, and 6 day cultures were chosen for
several reasons: First, we expected a priori that antigen-related
regulation is a slower, secondary response, to primary activation.
This assumption is in keeping with the observation that stimulation
of resting Treg reach maximal expression of FoxP3 34–44 h after
simulation [35]. Second, it is still not clear whether early
polyfunctionality actually persists over time, including early
markers for proliferation such as Ki-67 [32]. Third, a fundamental
element of effector lymphocytes is the ability to proliferate,
indicating responsiveness to IL-2 (via its receptor CD25), whereas
proinflammatory cytokines such as IFN-c upregulate HLA class II
(including DR) on T cells. Moreover, HIV-specific proliferative T
cell responses have been long known to associate with slow
progression [36]. Our assay use changes in CD25+HLA-DR+ as
readout, parameters that both reflect activation and proliferation,
the latter illustrated in Fig. 1A. Nevertheless, we appreciate that
our approach only reflect one out of several ways by which
classical ‘‘net’’ T cell responses can be estimated in vitro. Indeed,
other major regulatory pathways may influence overall activation.
Finally, in-depth interpretation and characterization of our assay
can certainly be extended, such as to address whether the ‘‘gain’’
in activation by blockade of regulatory pathways also provides an
increase in effector cell functions, such as cytotoxic capacity or
polyfunctionality.
A possible clinical relevance of this new exploratory parameter
was suggested by the significant correlations between RAC and the
classical prognostic markers CD38 and CD4 loss rates. These
correlations were not found for the activation results (Fig. 4). Even
if the study included only a limited number of cases, we were still
able to cover a wide spectrum of chronic immune activation. Gag-
specific T cell responses correlated negatively with concurrent
HIV RNA levels, an association also found in other and larger
study cohorts [37,38]. It should be noted that our group favours
bead-calibrated measures for CD38 density rather than the more
simple and conventional measure for HIV-associated chronic
immune activation, namely % CD38+HLA-DR+. We have
previously shown that CD38 density is even better related to
other progression markers [8,25,26].
Post-hoc we observed clusters of patients having either
particularly low (Low regulators) or high (High regulators)
regulation (i.e. RAC). The High regulators seemed to have more
rapid HIV progression, in keeping with our expectation. In
contrast, Low regulators had more favourable clinical character-
istics in terms of slower CD4 loss rates and higher CD8 counts
[39]. The levels of the proinflammatory cytokines TNF-a and
IFN-c were also higher in Low regulators. This has previously
been interpreted as a sign of unfavourable immune activation in
patients with lower CD4 counts [40,41]. From our data, derived
from patients with higher CD4 counts, one might conversely
speculate whether higher TNF-a and IFN-c levels rather reflect a
beneficial type of immune activation.
RAC or similar quantitative parameters for HIV antigen-specific
regulation should be further explored in larger cohorts. This may
help to better understand the complex interplay between
regulation and activation, to select patients for immune therapy
Figure 5. Relations between total CD3+ T cell activation and RAC induced by Env and Gag peptide panels. A. Relations between total
CD3+ T cell regulation calculated after Env and Gag peptide panel stimulations, respectively. Low regulators (+), Gag regulators (n) and Pan
regulators (X) indicated as defined in the text. B. Relations between total CD3+ T cell activation to Env and Gag, respectively, in the same patient
groups as in panel A.
doi:10.1371/journal.pone.0085604.g005
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studies, and to determine the prognostic significance of regulation.
Future studies should also explore the individual contribution of
IL-10 and TGF-ß along with other regulating mechanisms such as
CTLA-4 and PD-1. This was hampered by a scarcity of patients
and samples in this study. Both a broader range of HIV antigens
and even non-HIV antigens should be tested. In this study Gag
was selected based on the relation between Gag-specific T cell
responses to control viral replication [37,38] and Env as a relevant
antigen for HIV vaccines.
Figure 6. Distributions between regulator subgroups. Box and whisker plots representing medians, interquartile ranges and overall ranges for
cytokines in snap-frozen plasma (upper two panels), CD4 counts and CD4 loss rates (two middle panels) and CD8 counts as well as HIV RNA levels
(two lower panels). ‘‘Low regulators’’ (Low) as defined in the text are represented as one group, whereas the ‘‘High regulator’’ patients are split into
‘‘Gag regulators’’ (Gag) and ‘‘Pan regulators’’ (Pan), respectively. Significant differences p,0.05 between groups (Mann-Whitney) indicated (*).
doi:10.1371/journal.pone.0085604.g006
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Conclusions
In summary, this study on regulation of Gag- and Env-specific
T cell activation by IL-10 and TGF-ß (RAC) in chronic HIV
infection revealed heterogeneous levels of regulation between both
patients and HIV antigens. The magnitude of RAC was substantial
in some individuals and RAC could not be predicted by the
corresponding, classical antigen-specific activation parameters.
High RAC seemed clinically unfavourable, particularly when
induced by Env peptides. Thus, assessments of regulation deserve
further in-depth exploration and extension to larger cohorts.
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